Literature DB >> 18523800

Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction.

Markus Menges1, Thomas Hoehler.   

Abstract

Gastric cancer is a major health issue and a leading cause of death worldwide. The results of standard therapy remain unsatisfactory mainly because of diagnosis at the late stage of disease. Innovative strategies such as neoadjuvant chemotherapy in locally advanced cancer have improved the outcome even in operable cases. Whether an adjuvant radiochemotherapy is of benefit after curative resection including systematic lymphadenectomy remains yet unclear. Some progress has been made in the palliative setting by introducing new substances. This review examines recent advances in the systemic treatment of gastric and gastroesophageal junction cancer.

Entities:  

Mesh：

Year:  2008        PMID： 18523800     DOI： 10.1007/s00432-008-0425-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  55 in total

1.  Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente).

Authors:  E Mari; I Floriani; A Tinazzi; A Buda; M Belfiglio; M Valentini; S Cascinu; S Barni; R Labianca; V Torri
Journal:  Ann Oncol       Date:  2000-07       Impact factor: 32.976

Review 2.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Authors:  Anna D Wagner; Wilfried Grothe; Johannes Haerting; Gerhard Kleber; Axel Grothey; Wolfgang E Fleig
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

3.  Analysis of 154 actual five-year survivors of gastric cancer.

Authors:  S N Hochwald; S Kim; D S Klimstra; M F Brennan; M S Karpeh
Journal:  J Gastrointest Surg       Date:  2000 Sep-Oct       Impact factor: 3.452

4.  Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.

Authors:  Jaffer A Ajani; Fa-Chyi Lee; Deepti A Singh; Daniel G Haller; Heinz-Josef Lenz; Al B Benson; Ronald Yanagihara; Alexandria T Phan; James C Yao; Dirk Strumberg
Journal:  J Clin Oncol       Date:  2006-02-01       Impact factor: 44.544

Review 5.  Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction.

Authors:  M Pera
Journal:  Recent Results Cancer Res       Date:  2000

6.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

7.  Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial.

Authors:  A Lerner; R Gonin; G D Steele; R J Mayer
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

8.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

9.  Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil.

Authors:  J T Plukker; N H Mulder; D T Sleijfer; J Grond; R C Verschueren
Journal:  Br J Surg       Date:  1991-08       Impact factor: 6.939

10.  p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer.

Authors:  C Fondevila; J P Metges; J Fuster; J J Grau; A Palacín; A Castells; A Volant; M Pera
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640
View more
  19 in total

1.  Pre-operative lymph node status of gastric cancer evaluated by multidetector computed tomography.

Authors:  Min Wang; Yanwei Ye; Qing Yang; Jingjing Li; Chao Han; Wei Wang; Chunlin Zhao; Jianguo Wen
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 2.  Systematic review on quality of life outcomes after gastrectomy for gastric carcinoma.

Authors:  Bernard Shan; Leonard Shan; David Morris; Sanjeev Golani; Akshat Saxena
Journal:  J Gastrointest Oncol       Date:  2015-10

3.  Snail1 correlates with patient outcomes in E-cadherin-preserved gastroesophageal junction adenocarcinoma.

Authors:  H Dong; L Xie; C Tang; S Chen; Q Liu; Q Zhang; W Zheng; Z Zheng; H Zhang
Journal:  Clin Transl Oncol       Date:  2013-12-20       Impact factor: 3.405

4.  Gastric cancer: Where is the place for the surgeon, the oncologist and the endoscopist today?

Authors:  Markus Menges
Journal:  World J Gastrointest Oncol       Date:  2011-01-15

5.  Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway.

Authors:  Yubo Cao; Jinglei Qu; Ce Li; Dan Yang; Kezuo Hou; Huachuan Zheng; Yunpeng Liu; Xiujuan Qu
Journal:  Tumour Biol       Date:  2015-02-21

6.  Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis.

Authors:  Lei Ge; Hai-Jiang Wang; Dong Yin; Cheng Lei; Jin-Feng Zhu; Xiao-Hui Cai; Guo-Qing Zhang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

7.  TRPM2 channel-mediated regulation of autophagy maintains mitochondrial function and promotes gastric cancer cell survival via the JNK-signaling pathway.

Authors:  Shekoufeh Almasi; Barry E Kennedy; Mariam El-Aghil; Andra M Sterea; Shashi Gujar; Santiago Partida-Sánchez; Yassine El Hiani
Journal:  J Biol Chem       Date:  2018-01-17       Impact factor: 5.157

8.  A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population.

Authors:  Ming Xu; Guoquan Tao; Meiyun Kang; Yan Gao; Haixia Zhu; Weida Gong; Meilin Wang; Dongmei Wu; Zhengdong Zhang; Qinghong Zhao
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

9.  The metastasis-associated gene MTA3, a component of the Mi-2/NuRD transcriptional repression complex, predicts prognosis of gastroesophageal junction adenocarcinoma.

Authors:  Hongmei Dong; Hong Guo; Liangxi Xie; Geng Wang; Xueyun Zhong; Thaer Khoury; Dongfeng Tan; Hao Zhang
Journal:  PLoS One       Date:  2013-05-03       Impact factor: 3.240

10.  Detection and Characterization of Metastatic Cancer Cells in the Mesogastrium of Gastric Cancer Patients.

Authors:  Daxing Xie; Liang Liu; Hasan Osaiweran; Chaoran Yu; Fang Sheng; Chun Gao; Junbo Hu; Jianping Gong
Journal:  PLoS One       Date:  2015-11-13       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.